Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR407899 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Period 1: placebo Period 2: sildenafil Period 3: SAR407899 dose level 2 Period 4: SAR407899 dose level 1 |
| Sequence 2 | EXPERIMENTAL | Period 1: sildenafil Period 2: SAR407899 dose level 1 Period 3: placebo Period 4: SAR407899 dose level 2 |
| Sequence 3 | EXPERIMENTAL | Period 1: SAR407899 dose level 1 Period 2: SAR407899 dose level 2 Period 3: sildenafil Period 4: placebo |
| Sequence 4 | EXPERIMENTAL | Period 1: SAR407899 dose level 2 Period 2: placebo Period 3: SAR407899 dose level 1 Period 4: sildenafil |
| Name | Type | Description |
|---|---|---|
| SAR407899 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
| Sildenafil | DRUG | Oral administration |
Inclusion Criteria: * male with mild to moderate erectile dysfunction for at least 6 months * written informed consent Exclusion Criteria: * diabetes mellitus * orthostatic hypotension * hypogonadal testosterone level The above information is not intended to contain all considerations relevant t...
SAR407899 is an investigational small molecule being studied for the treatment of mild to moderate erectile dysfunction. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
SAR407899 is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug is currently in Phase 2 clinical trials for erectile dysfunction.
SAR407899 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still being evaluated in clinical trials for safety and efficacy.
SAR407899 has one completed Phase 2 clinical trial, identified as NCT00914277, titled 'SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction.' This randomized, double-blind, controlled study enrolled 24 male participants in France.
SAR407899 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for erectile dysfunction. The drug has completed one clinical trial but has not yet received regulatory approval.